<div id="readability-page-1"><div>** Shares of WuXi Biologics (Cayman) Inc climb 4.1% to HK$41.68, their highest level since October 9** Stock on track for a fifth straight session of gain** Co expects its 2025 profit attributable to equity shareholders to rise 46.3% y/y to 4.91 bln yuan ($710.21 mln)** Revenue seen up 16.7% at 21.79 bln yuan and the gross profit margin rate is expected to expand by 5 percentage points to 46%** Co says the increase is due to enlarged spectrum of services offered to the biologics industry, growth of research services revenue, cost savings and efficiency improvements, among others ** YTD, stock up 29.9%, the Hang Seng Biotech Index (.HSBIO) up 13.3%($1 = 6.9106 Chinese yuan)</div></div>

WuXi Biologics (Cayman) Inc shares rose 4.1% to HK$41.68, reaching a four-month high. The company anticipates a 46.3% increase in 2025 profit to 4.91 billion yuan ($710.21 million) and a 16.7% rise in revenue to 21.79 billion yuan. The gross profit margin is expected to improve by 5 percentage points to 46%. This growth is attributed to expanded services, increased research revenue, and efficiency improvements. Year-to-date, the stock is up 29.9%, outperforming the Hang Seng Biotech Index, which is up 13.3%.

Reuters

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

WUXI BIO

CAM HSBIOTECH

China Southern Hang Seng Biotech ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

WuXi Biologics climbs to 4-month high on robust earnings estimates